Last reviewed · How we verify
Flucelvax Trivalent Influenza Vaccine
Flucelvax Trivalent Influenza Vaccine is a Biologic drug developed by Seqirus. It is currently in Phase 2 development. Also known as: Flucelvax.
At a glance
| Generic name | Flucelvax Trivalent Influenza Vaccine |
|---|---|
| Also known as | Flucelvax |
| Sponsor | Seqirus |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flucelvax Trivalent Influenza Vaccine CI brief — competitive landscape report
- Flucelvax Trivalent Influenza Vaccine updates RSS · CI watch RSS
- Seqirus portfolio CI
Frequently asked questions about Flucelvax Trivalent Influenza Vaccine
What is Flucelvax Trivalent Influenza Vaccine?
Flucelvax Trivalent Influenza Vaccine is a Biologic drug developed by Seqirus.
Who makes Flucelvax Trivalent Influenza Vaccine?
Flucelvax Trivalent Influenza Vaccine is developed by Seqirus (see full Seqirus pipeline at /company/seqirus).
Is Flucelvax Trivalent Influenza Vaccine also known as anything else?
Flucelvax Trivalent Influenza Vaccine is also known as Flucelvax.
What development phase is Flucelvax Trivalent Influenza Vaccine in?
Flucelvax Trivalent Influenza Vaccine is in Phase 2.
Related
- Manufacturer: Seqirus — full pipeline
- Also known as: Flucelvax
- Compare: Flucelvax Trivalent Influenza Vaccine vs similar drugs
- Pricing: Flucelvax Trivalent Influenza Vaccine cost, discount & access